Amritsar Online

Malignant Pleural Mesothelioma Market, Epidemiology and Market Forecast – 2030

 Breaking News
  • No posts were found

Malignant Pleural Mesothelioma Market, Epidemiology and Market Forecast – 2030

July 27
04:42 2021
Malignant Pleural Mesothelioma Market, Epidemiology and Market Forecast - 2030

DelveInsight Business Research LLP
The Malignant Pleural Mesothelioma (MPM) market report provides current treatment practices, emerging drugs, MPM market share of the individual therapies, current and forecasted MPM market size from 2017 to 2030 segmented by seven major markets. The Report also covers current MPM treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses underlying potential of the market.

Malignant Pleural Mesothelioma Market

DelveInsight’s ‘Malignant Pleural Mesothelioma Market’ report delivers an in-depth understanding of the MPM, historical and forecasted epidemiology as well as the MPM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom), and Japan.

The MPM market report provides current treatment practices, emerging drugs, MPM market share of the individual therapies, current and forecasted MPM market size from 2017 to 2030 segmented by seven major markets. The Report also covers current MPM treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses underlying potential of the market.

Malignant Pleural Mesothelioma Drug Chapters

Drug chapter segment of the Malignant Pleural Mesothelioma report encloses the detailed analysis of Malignant Pleural Mesothelioma marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Malignant Pleural Mesothelioma clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Malignant Pleural Mesothelioma Marketed Drugs

Opdivo (Nivolumab): Bristol-Myers Squibb/ONO Pharmaceutical

Opdivo (Nivolumab) by Bristol-Myers Squibb is a human immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor PD-1, with immune checkpoint inhibitory and antineoplastic activities. In Japan, ONO launched Opdivo for the treatment of unresectable advanced or recurrent malignant pleural mesothelioma which has progressed after chemotherapy in August 2018. For MPM, it is approved only in Japan; however, in the US and Europe, it is currently in phase III clinical trial.

NovoTTF-100L System in Combination with Chemotherapy: NovoCure

NovoTTF-100L—a product of NovoCure is a noninvasive, antimitotic cancer treatment that delivers tumor treating fields to the region of the tumor, a therapy that uses electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. It has been approved by the US FDA for the first-line treatment of unresectable, locally advanced, or metastatic, malignant pleural mesothelioma. It is worth mentioning that, NovoCure has applied for CE certification to market NovoTTF-100L in the EU.

Products detail in the report…

Malignant Pleural Mesothelioma Emerging Drugs

TR002: Trizell

Trizell is evaluating its gene therapy TR002, an adenovirus-mediated interferon alfa 2b (rAd-IFN),in ongoing phase III clinical study in patients with malignant pleural mesothelioma who have failed the first-line standard of care chemotherapy. It is administered by catheter into the pleural cavity, where the virus enters the cells lining the pleural cavity. Inside the cells, the virus breaks down leaving the active gene to do its work. A previous Phase II study of TR002 is at Penn Medicine’s Abramson Cancer Center included 40 mesothelioma patients who were newly diagnosed or failed standard chemotherapy (Pemetrexed, and Cisplatin). Patients showed an overall disease control rate of 87.5%.

Imfinzi: AstraZeneca

Imfinzi (durvalumab; MEDI4736)—a product of AstraZeneca, is a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody.

PrECOG, a cancer research group formed as a not-for-profit limited liability company in 2006 by the ECOG Research and Education Foundation, with funding from AstraZeneca, has initiated clinical trials investigating Imfinzi, in first Line treatment in Advanced Pleural Mesothelioma patients. At present two clinical trials are ongoing, which are NCT02899195 (PrE0505), and NCT04334759 (DREAM3R).

Tecentriq Plus Avastin: Hoffmann-La Roche

Tecentriq (Atezolizumab) is a product of Roche. It is a programmed cell death ligand 1 (PD-L1) blocking antibody which works by blocking the action of a certain protein in cancer cells. This helps the immune system to fight against the cancer cells and helps to slow tumor growth. Presently, the company in collaboration with the European Thoracic Oncology Platform (Sponsor) is involved in a multicenter randomized Phase III trial (NCT03762018) comparing Atezolizumab plus Bevacizumab and standard chemotherapy vs. bevacizumab and standard chemotherapy as first-line treatment for Advanced Malignant Pleural Mesothelioma.

Pegargiminase: Polaris Pharmaceuticals

Pegargiminase (ADI‑PEG 20), an arginine degrading enzyme is a product of Polaris Pharmaceuticals currently being investigated in ATOMIC-Meso Phase II/III Study (NCT02709512) clinical study. Pegargiminase is administered by intramuscular injection and works by depleting the external supply of an amino acid called arginine.

MTG201 Plus Nivolumab: Momotaro-Gene

MTG201 is novel investigational gene therapy with unique dual mechanisms of action capable of addressing a range of cancers. In September 2019,

Momotaro-Gen announced enrollment of first patients with Relapsed Malignant Pleural Mesothelioma. The Phase II trial (NCT04013334), which is being conducted at the Baylor College of Medicine is an open-label, single-arm study designed to assess the efficacy, safety, and tolerability of intratumoral administration of MTG201 in combination with nivolumab. Apart from this, Momotaro-Gene has completed Phase I trial of MTG201, demonstrating encouraging safety and tolerability in patients with malignant. This study was conducted with relapsed malignant pleural mesothelioma patients in Japan by Kyorin Pharmaceuticals.

Products detail in the report…

Malignant Pleural Mesothelioma Market Outlook

Key Findings

According to DelveInsight, Malignant Pleural Mesothelioma market in the 7MM is expected to change in the study period 2017–2030. The therapeutic market of Malignant Pleural Mesothelioma in seven major markets was found to be USD 290 million in 2017 which is expected to increase during study period (2017–2030).

For sample pages of Malignant Pleural Mesothelioma Market, click here @ https://www.delveinsight.com/report-store/malignant-pleural-mesothelioma-market 

Media Contact
Company Name: DelveInsight
Contact Person: Priya Maurya
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/

Related Articles